CN117243963B - Use of Remodelin and Venetoclax in the treatment of cancer - Google Patents
Use of Remodelin and Venetoclax in the treatment of cancer Download PDFInfo
- Publication number
- CN117243963B CN117243963B CN202311177138.4A CN202311177138A CN117243963B CN 117243963 B CN117243963 B CN 117243963B CN 202311177138 A CN202311177138 A CN 202311177138A CN 117243963 B CN117243963 B CN 117243963B
- Authority
- CN
- China
- Prior art keywords
- venetoclax
- remodelin
- cancer
- pharmaceutically acceptable
- pharmaceutical combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229960001183 venetoclax Drugs 0.000 title claims abstract description 55
- XAEJIFARBQJLML-UHFFFAOYSA-N 4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CSC(NN=C2CCCC2)=N1 XAEJIFARBQJLML-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 201000011510 cancer Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 33
- 230000004083 survival effect Effects 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 206010041660 Splenomegaly Diseases 0.000 claims abstract description 5
- 230000002159 abnormal effect Effects 0.000 claims abstract description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 50
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- -1 pH regulators Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 229960001904 epirubicin Drugs 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229930183665 actinomycin Natural products 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- 230000003833 cell viability Effects 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 4
- 229960002066 vinorelbine Drugs 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 206010033661 Pancytopenia Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 208000024389 cytopenia Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 23
- 241000699670 Mus sp. Species 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 11
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 208000032839 leukemia Diseases 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 description 6
- 229950008166 valnemulin Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OSWZKAVBSQAVFI-UHFFFAOYSA-N 4-[(4-isothiocyanatophenyl)diazenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C=S)C=C1 OSWZKAVBSQAVFI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150000157 ARHGEF1 gene Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122597 Histone acetyltransferase inhibitor Drugs 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 1
- 101001024635 Homo sapiens RNA cytidine acetyltransferase Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000506 liquid--solid chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 101150055452 lsc gene Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000002814 testicular lymphoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to application of Remodelin and Venetoclax in treatment of cancers. The invention provides use of venetoclax and Remodelin in the manufacture of a medicament for the treatment of cancer. In vivo and in vitro experiments prove that the combined administration can inhibit the activity and proliferation of cancer cells, and the animal experiments show that the combination of the two medicines can obviously prolong the survival time of mice, relieve splenomegaly and reduce abnormal primitive cells.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of Remodelin and Venetoclax in treatment of cancers.
Background
Leukemia is one of ten major malignant tumors in China, acute myelogenous leukemia (Acute myeloid leukemia, AML) has large heterogeneity, complex pathogenesis, rapid progress, high recurrence drug resistance rate and high treatment cost, and brings heavy economic burden to families and society.
AML is a heterogeneous disease, AML cells of different patients possess different combinations of mutant genes, such as point mutations of IDH1, TET2, NPM1, CEBPA and RUNX1, and a series of chromosomal Structural Variations (SV), such as inv (3), inv (16), t (8; 21), t (9; 22) and t (6; 9), etc. Chromosomal translocation is the most common genetic abnormality of AML, and the resulting fusion gene is often an important driver for AML occurrence and progression. Wherein T (8; 21) (q 22; q 22) is the most common type of chromosomal translocation in clinic, i.e., translocation results in fusion of the ETO gene located on chromosome 8 with the AML1 gene located on chromosome 21, forming an AML1-ETO fusion gene (also known as RUNX1-RUNX1T1 fusion gene), whose expressed and produced proteins affect normal differentiation of hematopoietic stem cells via various pathways, resulting in arrest of myeloid differentiation, resulting in the occurrence of leukemia. t (8; 21) AML accounts for 12-15% of all AMLs, and up to 40% -60% of M2 type AMLs. t (8; 21) AML prognosis is good, with overall remission rates as high as 60%.
Nevertheless, the long-term survival rate caused by high drug resistance and recurrence rate is still a difficult problem faced by clinic, and the survival rate of 3 years is less than 35.5% according to the data monitored by the national cancer institute. At its root, the presence of leukemia stem cells (leukemia stem cell, LSCs) is the source of AML drug-resistant recurrence. However, the regulatory mechanism of t (8; 21) AML leukemia stem cells is not completely elucidated, the regulatory mechanism of stem cell function maintenance is explored, the mechanism of t (8; 21) AML drug resistance relapse and treatment difficulty is deeply recognized, and new means and strategies are provided for clinical diagnosis and treatment.
Venetian (Venetoclax, ABT-199) is a novel Bcl-2 selective inhibitor, also known as Venetian, venetitolla, and can be used in combination with azacitidine, decitabine or low dose cytarabine for treating AML patients over 75 years old. Although valnemulin demonstrated good clinical efficacy, some AML patients developed relapse, resistance to drugs, and eventually died after treatment with valnemulin. The drug has natural drug resistance or acquired drug resistance to the valnemulin, which is a great obstacle for treating AML by clinically applying the valnemulin. Therefore, further discussing the drug resistance mechanism of valnemulin, finding a novel therapeutic strategy to enhance the anti-AML activity of valnemulin has particular importance and urgency for improving the cure rate of AML.
Disclosure of Invention
The invention provides venetoclax and remodelin combined administration for treating cancer for the first time, and in vivo and in vitro experiments prove that the combined administration can inhibit the activity and proliferation of cancer cells, and in animal experiments, the two-drug combination can obviously prolong the survival time of mice, relieve splenomegaly and reduce abnormal primitive cells.
Specifically, the invention provides the following technical scheme:
In a first aspect, the present invention provides a pharmaceutical combination composition having the effect of preventing, alleviating and treating cancer, comprising: 1) venetoclax and pharmaceutically acceptable salts thereof, and 2) Remodelin and pharmaceutically acceptable salts thereof.
Preferably, the pharmaceutical combination composition further comprises pharmaceutically acceptable excipients, wherein the pharmaceutically acceptable excipients comprise any one or a combination of at least two of diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, bacteriostats or buffers.
The dosage form and the mode of administration of the pharmaceutical combination composition of the present invention are not particularly limited. Representative modes of administration include, but are not limited to: oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection, and topical administration.
In a specific embodiment, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, e.g., glycerin; (d) Disintegrants, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent, such as paraffin; (f) an absorption accelerator, e.g., a quaternary amine compound; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) an adsorbent, for example, kaolin; and (i) a lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents. Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
In a specific embodiment, the liquid dosage form for oral administration comprises a pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances. In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Such as suspensions, may contain suspending agents as, for example, particularly ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances.
In a particular embodiment, a composition for parenteral injection may comprise a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion. Suitable aqueous or nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
In a specific embodiment, the dosage forms for topical administration include ointments, powders, patches, sprays and inhalants. Is prepared by mixing the active ingredient under aseptic condition with pharmaceutically acceptable carrier and any preservative, buffer or propellant as required.
Preferably, the pharmaceutical combination composition may be administered orally.
Preferably, the dosage form of the pharmaceutical combination composition comprises a capsule, a tablet, a pill, a powder, a granule, an emulsion, a solution, a suspension, a syrup or a tincture.
In a specific embodiment, the pharmaceutical combination composition comprises 1) venetoclax and pharmaceutically acceptable salts thereof, and 2) Remodelin and pharmaceutically acceptable salts thereof in the same or different dosage forms.
In a specific embodiment, 1) venetoclax and pharmaceutically acceptable salts thereof, and 2) Remodelin and pharmaceutically acceptable salts thereof, are administered simultaneously or sequentially, in particular, may be administered at intervals of 0,1, 2,3,4,5,6, 7 or more days.
In a specific embodiment, the dosage ratio of 1) venetoclax and pharmaceutically acceptable salts thereof, and 2) Remodelin and pharmaceutically acceptable salts thereof in the pharmaceutical combination composition is 1:0.1-2; specifically included are 3:1, 2:1, 1:1, 1:2, 1:3.
Preferably, the mass ratio of the two main active ingredients in the pharmaceutical combination composition is 1:1.
Most preferably, the effective dose of venetoclax is 100-600 mg/day.
Most preferably, the effective dose of Remodelin is 100-600 mg/day.
Preferably, other cancer drugs such as doxorubicin, vincristine, vinorelbine, paclitaxel, cisplatin, actinomycin, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, epirubicin, etoposide, podophyllotoxin, etoposide, and the like may also be included in the pharmaceutical combination composition.
In another aspect, the invention provides the use of venetoclax and Remodelin in the manufacture of a medicament for the treatment of cancer.
In particular, the manifestations of treating cancer include prolonged survival, remission of splenomegaly, and abnormal primordial cytopenia.
Preferably venetoclax and Remodelin are administered simultaneously or sequentially;
Preferably, venetoclax and Remodelin are also useful in combination with other anti-cancer drugs and cancer treatments.
Specifically, the other anticancer drugs are exemplified by doxorubicin, vincristine, vinorelbine, taxol, cisplatin, actinomycin, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, epirubicin, etoposide, podophyllotoxin, fluoroarabinoic acid, and the like. Other cancer treatment modalities such as: chemotherapy, radiation therapy, immunotherapy, gene therapy, surgery, etc.
As is well known to those skilled in the art, the effective dosages (administered dosages) of venetoclax and Remodelin vary depending on the route of administration, the use of excipients, and co-administration with other therapeutic modalities.
In another aspect, the invention provides use of Remodelin in the manufacture of a product for the treatment of cancer, reducing the toxic side effects of venetoclax.
In another aspect, the invention also provides a method of treating cancer comprising administering Remodelin and venetoclax to a cancer patient.
Examples of cancers described herein include, but are not limited to, cervical cancer, seminoma, testicular lymphoma, prostate cancer, ovarian cancer, lung cancer (e.g., small cell lung cancer SCLC, non-small cell lung cancer NSCLC, lung adenocarcinoma), rectal cancer, breast cancer, cutaneous squamous cell carcinoma, colon cancer, liver cancer, pancreatic cancer, esophageal cancer, thyroid cancer, transitional bladder epithelial cancer, leukemia (e.g., acute lymphoblastic leukemia ALL, acute myelogenous leukemia AML, chronic myelogenous leukemia CML, chronic lymphocytic leukemia CLL), brain tumor, gastric cancer, peritoneal cancer, head and neck cancer, endometrial cancer, kidney cancer, female genital tract cancer, carcinoma in situ, neurofibromatosis, bone cancer, skin cancer, gastrointestinal stromal tumors, mast cell tumors, multiple myeloma, melanoma, glioma.
Preferably, the cancer of the invention is an Acute Myeloid Leukemia (AML), a group of malignant clonal diseases of hematopoietic tissue origin characterized by abnormal primitive cell accumulation and by a disorder of normal blood cell production and differentiation.
Preferably, the cancer is acute myelogenous leukemia AML.
Preferably, the cancer is AML of the following subtype: inv (3), inv (16), t (8; 21), t (9; 22) and t (6; 9).
More preferably, the cancer is AML of subtype t (8; 21), i.e. with 8: chromosome 21-translocated AML.
More preferably, the AML comprises relapsed AML, refractory AML.
The term "Venetoclax (valneturab, valnemtock, vantolx, ABT-199, GDC-0199)" as described herein is the first small molecule inhibitor of protein-protein interactions (PPI) worldwide, a highly potent, selective and orally active small molecule Bcl-2 inhibitor that binds to the hydrophobic groove of Bcl-2, disrupting Bcl-2 molecule interactions with pro-apoptotic proteins (such as Bax). The Venetoclax includes Venetoclax pharmaceutically acceptable salts.
The term "Remodelin (Histone Acetyltransferase inhibitor)" as used herein is known to be a potent acetyl-TRANSFERASE NAT10 inhibitor under the chemical name 4- (N, N-dimethylamino) azobenzene-4' -isothiocyanate. The Remodelin includes Remodelin pharmaceutically acceptable salts.
In another aspect, the invention provides a method of inhibiting cell viability of AML cells comprising the step of administering venetoclax and Remodelin.
Preferably, the method is non-therapeutic.
More specifically, the AML cells include Kasumi-1, SKNO-1 or cells from AML patients.
The beneficial effects are that:
The mode of jointly dosing venetoclax and Remodelin provided by the invention not only reduces the dosage of venetoclax and reduces toxic and side effects, but also achieves the effect of cooperative treatment.
Drawings
FIG. 1 is a result of verifying venetoclax and Remodelin synergistic effects in Kasumi-1 cells.
FIG. 2 is a result of verifying the synergistic effect of venetoclax and Remodelin in SKNO-1 cells.
Figure 3 is the result of validation venetoclax and Remodelin synergistic effects in AML clinical sample cells.
Fig. 4 is a representative view of the spleen of mice after drug treatment.
Fig. 5 is a graph of the statistical results of spleen weights after drug treatment.
FIG. 6 is a graph of statistical results of leukemia cell numbers in mouse bone marrow using flow assays.
Fig. 7 is a graph of survival of AML mice after treatment.
FIG. 8 is a graph of Giemsa staining results of peripheral blood smears of mouse tails.
FIG. 9 is a graph of HE staining results.
Detailed Description
The present invention is further described in terms of the following examples, which are given by way of illustration only, and not by way of limitation, of the present invention, and any person skilled in the art may make any modifications to the equivalent examples using the teachings disclosed above. Any simple modification or equivalent variation of the following embodiments according to the technical substance of the present invention falls within the scope of the present invention.
Example 1 determination of the Combined Effect of two drugs Using the MTS method
The operation steps are as follows:
The cells were counted, ensuring a cell viability of greater than 95% and the cell concentration was adjusted to 4X 10 5/ml with medium. Volume per well: 50 μl, i.e. cell number per well: 2X 10 4.
Performing multiple dilution on Remodelin with RPMI-1640 medium according to the solubility of the medicine, wherein the final concentration is 0, 1.25, 2.5, 5, 10, 20 and 40 mu M; venetoclax was also subjected to a double dilution, and Kasumi-1 cells were set to 0, 12.5, 25, 50, 100, 200nM, and SKNO-1 was set to 0, 0.5, 1, 2,4, 8. Mu.M due to the different sensitivity of the cells to the drug.
Mu.l of each of the drugs Venetoclax and Remodelin was added to the corresponding well of the 96-well plate to make the total volume 100. Mu.l. 4 secondary wells were provided for each concentration. The single drug well was supplemented with 25. Mu. LRPMI-1640 medium and the control well was supplemented with 50. Mu.L medium.
The culture was performed at 37℃for 68 hours in an incubator, and 10. Mu.L of MTS mixture (MTS: PMS=20:1) was added thereto, followed by treatment for 4 hours. OD 490 values were read with a microplate reader.
IC 50 values (drug concentration at 50% inhibition of cells) were calculated using GRAPHPAD PRISM software and standard isobolograms were made to evaluate the combined effect of the two drugs.
Experimental results:
The results are shown in fig. 1-2, with the dots in the graph representing: IC50 values for Remodelin at venetoclax concentrations. In the figure, a point falling below the oblique line represents that the two-medicine combination has a synergistic effect, a point falling on the oblique line represents that the two-medicine combination has a superposition effect, and a point falling outside the oblique line represents that the two-medicine combination has an antagonistic effect. Results show that Remodelin and Venetoclax combined can synergistically inhibit the activity of AML cells, and the two medicines combined have synergistic anti-AML activity.
Example 2, validation of the synergistic Effect of venetoclax and Remodelin in AML clinical sample cells
The operation steps are as follows:
the cells were counted, ensuring a cell viability of greater than 95% and the cell concentration was adjusted to a 2X 10 6/ml, 500. Mu.l system with medium. Set up into 4 groups, divided into the vehicle, remodelin, venetoclax, remodelin and Venetoclax combination groups.
Remodelin was added to adjust the final concentration to 10. Mu.M, venetoclax was added to adjust the final concentration to 200nM, and the cells in the well plate were thoroughly mixed with the drug.
After 24h of drug action, counting was started. The effect of the combination of the two drugs on AML cell proliferation was assessed by counting with trypan blue dye for 7 consecutive days and using GRAPHPAD PRISM software statistics.
Experimental results:
The results are shown in FIG. 3, where the dots represent the number of cells counted daily and the cell proliferation potency was measured using trypan blue dynamic 7 day counting continuously after the Remodelin and Venetoclax drugs were administered in the t (8; 21) AML samples. * P <0.05, < P <0.01, < P <0.001; one-way ANOVA post hoc comparisons, tukey's test. This result demonstrates that Remodelin in combination with Venetoclax synergistically inhibit AML cell proliferation and is superior to single agents.
Example 3 verification of synergistic Effect of venetoclax and Remodelin in animal models
Preparing the medicine:
Remodelin: working solution concentration 10mg/ml, formula: 20%DMSO+65%PEG300+15%TWEEN 80; preparing 50mg/ml mother liquor, dissolving 400mg of medicine in 8000 μl DMSO solution, subpackaging into 800 μl/branch, freezing at-80deg.C, adding 2600 μl lPEG300,300 into 800 μl DMSO mother liquor, clarifying, adding 600 μl TWEEN80, and mixing.
Venetoclax: working solution concentration 10mg/ml, formula: 5% DMSO+50% PEG300+5% TWEEN80+40% ddH 2 O; preparing 200mg/ml mother liquor, dissolving 400mg of medicine in 2000 mu l of DMSO solution, subpackaging into 200 mu l/branch, freezing at-80 ℃, adding 2000 mu l of PEG300 into 200 mu l of DMSO mother liquor for standby, adding 200 mu l of TWEEN80 after evenly mixing and clarifying, and adding 1600 mu lddH 2 O for use.
The operation steps are as follows:
3C 57BL/6J male mice, weighing 18-22g, were harvested at 6-8 weeks of age, 6 female mice were tethered after overnight mating, female mice were sacrificed at 14.5 days after cervical amputation to obtain fetal liver cells, cells were infected 2 times with MSCV-AML-ETO9a-IRES-tNGFR retrovirus (AML 1-ETO9a isomer is a fusion gene that resulted in t (8; 21) AML), erythrocytes were lysed, 1X 10 6 cells were counted, and the tail vein was injected into 750cGy irradiated recipient mice.
After waiting 21 days for leukemia to develop in the mice, the mice were euthanized, spleen and bone marrow cells were taken, 1×10 6 cells were counted, and the cells were transplanted into 450cGy irradiated recipient mice.
Mice were divided into 4 groups, a combination of vehicle, remodelin, venetoclax, remodelin and Venetoclax, respectively, and a group of 6. The following day, the treatment was administered by gavage, remodelin mg/kg, venetoclax mg/kg, for 14 consecutive days. After euthanasia of half of the mice, the mice were dissected, bone marrow and spleen cells were harvested, flow stained, and HE stained for spleen changes. The other half of the mice continued to be carefully attended to and the mice were monitored for survival.
Experimental results:
Fig. 4: spleen representative of mice after drug treatment. Fig. 5: spleen weight after drug treatment. Fig. 6: leukemia cells in mouse bone marrow were detected using flow-through. Fig. 7: after treatment, continuous observation was performed to count survival of AML mice. Survival graph 8 was plotted with Kaplan-Merier: peripheral blood smears were taken from the mouse tails, giemsa stained, and primordial cell ratios were observed. Fig. 9: HE staining observed spleen lesions. * P <0.05, < P <0.01, < P <0.001.
The results in this section show that the survival time of mice is prolonged after the combination treatment of the two drugs, and leukemia cells in bone marrow are reduced. Peripheral blood smears were seen with primitive granulocytes, promyelocytes in the Vehicle and venetoclax groups, and mature granulocytes in the remodelin and combination groups. Both drugs can relieve splenomegaly of AML mice, reduce lesions and have better combined effect.
Claims (17)
1. A pharmaceutical combination composition having the function of preventing, alleviating and treating cancer, said pharmaceutical combination composition consisting of: 1) venetoclax and pharmaceutically acceptable salts thereof, and 2) Remodelin and pharmaceutically acceptable salts thereof; venetoclax and pharmaceutically acceptable salts thereof and Remodelin and pharmaceutically acceptable salts thereof are present in a 1:1 dose ratio.
2. The pharmaceutical combination composition of claim 1, further comprising pharmaceutically acceptable excipients comprising any one or a combination of at least two of excipients, binders, wetting agents, disintegrants, emulsifiers, co-solvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, bacteriostats or buffers.
3. The pharmaceutical combination composition of claim 1, which is administered orally, nasally, intravenously, intra-arterially, intradermally, subcutaneously, intramuscularly, intraperitoneally, intrapleurally, intravaginally, intraurethrally, intratumorally, intracranially, intrathecally.
4. The pharmaceutical combination composition of claim 1, wherein the dosage form of the pharmaceutical combination composition comprises a capsule, a tablet, a pill, a powder, a granule, an emulsion, a solution, a suspension, a syrup, or a tincture.
5. The pharmaceutical combination composition of claim 1, wherein the dosage forms of venetoclax and pharmaceutically acceptable salts thereof and Remodelin and pharmaceutically acceptable salts thereof are the same or different.
6. The pharmaceutical combination composition of claim 1, further comprising any one or more of the following: doxorubicin, vincristine, vinorelbine, taxol, cisplatin, actinomycin, bleomycin, busulfan, capecitabine, carboplatin, carmustine chlorambucil, cyclophosphamide, cytarabine daunorubicin, epirubicin, and process for preparing the same daunorubicin, erythromycin epirubicin.
Use of venetoclax and Remodelin in the manufacture of a medicament for the treatment of cancer which is acute myelogenous leukemia, the dose ratio of venetoclax to Remodelin being 1:1.
8. The use of claim 7, wherein the manifestation of treating cancer comprises increased survival, relief of splenomegaly and abnormal primordial cytopenia.
9. The use of claim 7, wherein the cancer is acute myelogenous leukemia of the following subtype: inv (3), inv (16), t (8; 21), t (9; 22) and t (6; 9).
10. The use according to claim 7, wherein the cancer is acute myelogenous leukemia of subtype t (8; 21).
11. The use of claim 7, wherein said venetoclax and Remodelin are each independently administered orally, nasally, intravenously, intra-arterially, intradermally, subcutaneously, intramuscularly, intraperitoneally, intrapleurally, intravaginally, intraurethrally, intratumorally, intracranially, intrathecally.
12. The use of claim 7, wherein the dosage forms venetoclax and Remodelin, each independently, comprise a capsule, tablet, pill, powder, granule, emulsion, solution, suspension, syrup, or tincture.
13. The use of claim 7, wherein venetoclax and Remodelin are used in combination with other anti-cancer drugs and cancer treatments.
14. The use of claim 13, wherein the additional anticancer agent comprises doxorubicin, vincristine, vinorelbine, paclitaxel, cisplatin, actinomycin, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, epirubicin, etoposide, valicariine, fluoroarabinoadec acid.
15. The use of claim 13, wherein the other cancer treatment regimen comprises chemotherapy, radiation therapy, immunotherapy, gene therapy, surgery.
16. A method of inhibiting cell viability of acute myeloid leukemia cells, said method comprising the step of administering venetoclax and Remodelin, said method being non-therapeutic; the dosage ratio of venetoclax and Remodelin was 1:1.
17. The method of claim 16, wherein the acute myeloid leukemia cells comprise Kasumi-1, SKNO-1 or cells from AML patients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311177138.4A CN117243963B (en) | 2023-09-13 | 2023-09-13 | Use of Remodelin and Venetoclax in the treatment of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311177138.4A CN117243963B (en) | 2023-09-13 | 2023-09-13 | Use of Remodelin and Venetoclax in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117243963A CN117243963A (en) | 2023-12-19 |
| CN117243963B true CN117243963B (en) | 2024-08-13 |
Family
ID=89132351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311177138.4A Active CN117243963B (en) | 2023-09-13 | 2023-09-13 | Use of Remodelin and Venetoclax in the treatment of cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117243963B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114949230A (en) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12083136B2 (en) * | 2018-07-31 | 2024-09-10 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof |
| WO2021216754A1 (en) * | 2020-04-21 | 2021-10-28 | Spring Discovery, Inc. | Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system |
| TW202227089A (en) * | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | Combination therapy for the treatment of pik3ca mutant cancer |
| CN115531547B (en) * | 2022-10-18 | 2023-08-18 | 厦门大学附属第一医院 | Combined pharmaceutical composition with effects of preventing, relieving or treating acute myelogenous leukemia and application thereof |
| CN116270644A (en) * | 2023-05-22 | 2023-06-23 | 劲方医药科技(上海)有限公司 | Pharmaceutical combination of CDK9 inhibitor and BCL-2 inhibitor and application thereof |
-
2023
- 2023-09-13 CN CN202311177138.4A patent/CN117243963B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114949230A (en) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Jie Zi等.Targeting NAT10 Induces Apoptosis Associated With Enhancing Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Cells.Frontiers in Oncology.2020,第第10卷卷第4页左栏第1段. * |
| Targeting NAT10 Induces Apoptosis Associated With Enhancing Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Cells;Jie Zi等;Frontiers in Oncology;20201217;第第10卷卷;第4页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117243963A (en) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2429838C2 (en) | Combined chemotherapy | |
| JP2009263371A (en) | Anti-cancer combination | |
| TW200412937A (en) | Combination chemotherapy | |
| US12083136B2 (en) | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof | |
| US20220000835A1 (en) | Method for treating cancer with a combination of quercetin and a chemotherapy agent | |
| UA80552C2 (en) | Combined drug of the antitumoral derivative indolopyrrolocarbazole and other antitumoral agent and its application at cancer treatment | |
| EP3429614B1 (en) | Method of treating triple negative breast cancer | |
| CN111558044B (en) | Pharmaceutical composition containing sunitinib, and preparation and application thereof | |
| WO2013086002A1 (en) | Compositions, process of preparation of said compositions and method of treating cancer | |
| JP2024531492A (en) | Treatment of patients resistant to PARP inhibitors with TH-302 | |
| CN103930113B (en) | For preventing and treat the compositions comprising pyrazine pyrrolotriazine derivatives of nonsmall-cell lung cancer | |
| US20210290570A1 (en) | Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent | |
| KR102011105B1 (en) | pharmaceutical composition for prevention or treatment of pancreatic cancer comprising a gossypol and a phenformin | |
| CN117243963B (en) | Use of Remodelin and Venetoclax in the treatment of cancer | |
| CN115364109B (en) | Pharmaceutical preparation for treating lung cancer | |
| JP2024125140A (en) | Antitumor pharmaceutical composition comprising azuvidine and a chemotherapeutic agent | |
| CN115135326B (en) | Combination pharmaceutical composition of compounds as c-Met kinase inhibitors and use thereof | |
| CN116850289A (en) | Application of PLK4 targeted drug in treatment of platinum drug resistant tumor | |
| JP7311177B2 (en) | Combined use of A-NOR-5α androstane drugs with anticancer drugs | |
| CN118843466A (en) | Method for treating small cell lung cancer | |
| US20230117545A1 (en) | Pharmaceutical composition comprising protein kinase inhibitor and chemotherapeutic drug and use thereof | |
| KR20220124739A (en) | Combination Therapy for the Treatment of Cancer | |
| JP2022542725A (en) | Application of the compound or its pharmaceutically acceptable salt, dimer or trimer in the preparation of pharmaceuticals for treating cancer | |
| EA011573B1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| CN110179804B (en) | Application of Reversan in preparation of medicine for preventing and treating heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240710 Address after: No.3688 Nanhai Avenue, Nanshan District, Shenzhen, Guangdong 518061 Applicant after: SHENZHEN University Country or region after: China Applicant after: SHENZHEN UNIVERSITY GENERAL Hospital Address before: No. 1098, Xueyuan Avenue, University Town, Taoyuan Street, Nanshan District, Shenzhen, Guangdong 518055 Applicant before: SHENZHEN UNIVERSITY GENERAL Hospital Country or region before: China |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |